Meeting News Coverage

Eight research highlights from the AAD annual meeting

SAN FRANCISCO — A study showing that more than 20% of patients in a database with vitiligo had at least one comorbid disease was the most-read research article from Healio.com/Dermatology’s coverage of the American Academy of Dermatology Annual Meeting.

Other widely read research articles included new psoriasis therapies presented at a late-breaking research session, such as a novel interleukin-23 inhibitor and long-term data on Cosentyx (secukinumab, Novartis) therapy.

1. Research shows more than 20% of patients with vitiligo have at least one comorbid autoimmune disease

More than 20% of patients with vitiligo in a Detroit hospital database had at least one comorbid autoimmune disease, according to research reported in a poster presentation here.

Ilefat Hamzavi, MD

Iltefat Hamzavi

Iltefat Hamzavi, MD, FAAD, and colleagues searched the Henry Ford Medical Record Database to identify 1,873 patients with vitiligo who were seen between Jan. 1, 2002, and Oct. 31, 2012. After a manual review of the patients’ electronic records, 1,098 patients were included in the study analysis. Read more.

2. Psoriasis therapies dominate first late-breaking research session at AAD

Seven of the first 10 late-breaking research abstracts presented at the American Academy of Dermatology Annual Meeting focused on new therapies being investigated for the treatment of psoriasis.

Joel Gelfand, MD

Joel Gelfand

“We’re making major progress in people with psoriasis,” Joel Gelfand, MD, a moderator of the research session, told Healio.com/Dermatology. “The newer drugs coming to market all seem to have much higher clearance rates than we ever thought imaginably possible.” Read more.

3. Study: IL-23 inhibitor more effective than Stelara in treating psoriasis

In this video, Kim Papp, MD, PhD, discusses the late-breaking research he presented on a phase 2 study of a novel interleukin-23 inhibitor compared with Stelara in patients with moderate-to-severe plaque psoriasis.

Papp and colleagues found BI 655066 (Boehringer Ingelheim), a selective interleukin (IL)-23p19 antagonist monoclonal antibody, was more effective than Stelara (ustekinumab, Janssen) in achieving Psoriasis Area Severity Index 90 score at week 12, the study’s primary endpoint. Watch video.

4. Solid organ transplant recipients at higher risk for skin cancer

Sarah Aaron

Sarah T. Arron

In this video, Sarah Tuttleton Arron, MD, PhD, FAAD, discusses her research on mortality from skin cancer after solid organ transplantation, which she presented during a late-breaking research symposium here.

Tuttleton, an associate professor of dermatology at University of California in San Francisco and the lead investigator for the AAD Transplant Skin Cancer Network, and colleagues used data from 531,675 transplant recipients in the Organ Procurement and Transplantation registry. Watch video.

5. Novel boron-based ointment safe for treatment of atopic dermatitis in children

AN2728 ointment 2%, a novel boron-based small-molecule ointment, may be effective for the treatment of patients ages 2 years and older with mild-to-moderate atopic dermatitis, according to research presented during a late-breaking research session. Read more.

6. Long-term Cosentyx effectively treats patients with psoriasis

Seventy percent of patients with psoriasis had clear or almost clear skin after 2 years of therapy with Cosentyx 300 mg, according to late-breaking research presented.

“We are pleased to share new long-term data showing how the sustained efficacy and favorable safety profile of Cosentyx [secukinumab, Novartis] helps psoriasis patients maintain clear or almost clear skin,” Vasant Narasimhan, MD, global head of development at Novartis Pharmaceuticals, said in a press release. Read more.

7. Patients with psoriasis may be at increased risk for hospitalized pneumonia

Patients with psoriasis appeared to be at increased risk for pneumonia requiring hospitalization, according to late-breaking research presented here.

Junko Takeshita

Junko Takeshita

“Psoriasis, overall, is associated with an approximately 30% increased risk of pneumonia requiring hospitalization, independent of other risk factors for such as smoking, drinking, comorbid diseases and pneumonia vaccination,” researcher Junko Takeshita, MD, PhD, told Healio.com/Dermatology. “The risk of hospitalized pneumonia increases with greater psoriasis severity.” Read more.

8. Study: Juvéderm demonstrates greater improvement than Belotero in treating perioral lines

Juvéderm showed a higher response rate and greater improvement in the treatment of moderate-to-severe perioral lines compared with Belotero, according to research presented at a late-breaking research session.

Kimberly Butterwick, MD

Kimberly Butterwick

Kimberly Butterwick, MD, and colleagues conducted a 6-month, double-blind, controlled, multicenter study comparing Juvéderm Ultra (24 mg/mL hyaluronic acid, 0.3% lidocaine; HYC-24L, Allergan) with Belotero Balance (22.5 mg/ml hyaluronic acid; CPM-22.5, Merz Aesthetics) as treatment for 136 adults who had moderate-to-severe perioral lines. Read more.

SAN FRANCISCO — A study showing that more than 20% of patients in a database with vitiligo had at least one comorbid disease was the most-read research article from Healio.com/Dermatology’s coverage of the American Academy of Dermatology Annual Meeting.

Other widely read research articles included new psoriasis therapies presented at a late-breaking research session, such as a novel interleukin-23 inhibitor and long-term data on Cosentyx (secukinumab, Novartis) therapy.

1. Research shows more than 20% of patients with vitiligo have at least one comorbid autoimmune disease

More than 20% of patients with vitiligo in a Detroit hospital database had at least one comorbid autoimmune disease, according to research reported in a poster presentation here.

Ilefat Hamzavi, MD

Iltefat Hamzavi

Iltefat Hamzavi, MD, FAAD, and colleagues searched the Henry Ford Medical Record Database to identify 1,873 patients with vitiligo who were seen between Jan. 1, 2002, and Oct. 31, 2012. After a manual review of the patients’ electronic records, 1,098 patients were included in the study analysis. Read more.

2. Psoriasis therapies dominate first late-breaking research session at AAD

Seven of the first 10 late-breaking research abstracts presented at the American Academy of Dermatology Annual Meeting focused on new therapies being investigated for the treatment of psoriasis.

Joel Gelfand, MD

Joel Gelfand

“We’re making major progress in people with psoriasis,” Joel Gelfand, MD, a moderator of the research session, told Healio.com/Dermatology. “The newer drugs coming to market all seem to have much higher clearance rates than we ever thought imaginably possible.” Read more.

3. Study: IL-23 inhibitor more effective than Stelara in treating psoriasis

In this video, Kim Papp, MD, PhD, discusses the late-breaking research he presented on a phase 2 study of a novel interleukin-23 inhibitor compared with Stelara in patients with moderate-to-severe plaque psoriasis.

Papp and colleagues found BI 655066 (Boehringer Ingelheim), a selective interleukin (IL)-23p19 antagonist monoclonal antibody, was more effective than Stelara (ustekinumab, Janssen) in achieving Psoriasis Area Severity Index 90 score at week 12, the study’s primary endpoint. Watch video.

4. Solid organ transplant recipients at higher risk for skin cancer

Sarah Aaron

Sarah T. Arron

In this video, Sarah Tuttleton Arron, MD, PhD, FAAD, discusses her research on mortality from skin cancer after solid organ transplantation, which she presented during a late-breaking research symposium here.

Tuttleton, an associate professor of dermatology at University of California in San Francisco and the lead investigator for the AAD Transplant Skin Cancer Network, and colleagues used data from 531,675 transplant recipients in the Organ Procurement and Transplantation registry. Watch video.

PAGE BREAK

5. Novel boron-based ointment safe for treatment of atopic dermatitis in children

AN2728 ointment 2%, a novel boron-based small-molecule ointment, may be effective for the treatment of patients ages 2 years and older with mild-to-moderate atopic dermatitis, according to research presented during a late-breaking research session. Read more.

6. Long-term Cosentyx effectively treats patients with psoriasis

Seventy percent of patients with psoriasis had clear or almost clear skin after 2 years of therapy with Cosentyx 300 mg, according to late-breaking research presented.

“We are pleased to share new long-term data showing how the sustained efficacy and favorable safety profile of Cosentyx [secukinumab, Novartis] helps psoriasis patients maintain clear or almost clear skin,” Vasant Narasimhan, MD, global head of development at Novartis Pharmaceuticals, said in a press release. Read more.

7. Patients with psoriasis may be at increased risk for hospitalized pneumonia

Patients with psoriasis appeared to be at increased risk for pneumonia requiring hospitalization, according to late-breaking research presented here.

Junko Takeshita

Junko Takeshita

“Psoriasis, overall, is associated with an approximately 30% increased risk of pneumonia requiring hospitalization, independent of other risk factors for such as smoking, drinking, comorbid diseases and pneumonia vaccination,” researcher Junko Takeshita, MD, PhD, told Healio.com/Dermatology. “The risk of hospitalized pneumonia increases with greater psoriasis severity.” Read more.

8. Study: Juvéderm demonstrates greater improvement than Belotero in treating perioral lines

Juvéderm showed a higher response rate and greater improvement in the treatment of moderate-to-severe perioral lines compared with Belotero, according to research presented at a late-breaking research session.

Kimberly Butterwick, MD

Kimberly Butterwick

Kimberly Butterwick, MD, and colleagues conducted a 6-month, double-blind, controlled, multicenter study comparing Juvéderm Ultra (24 mg/mL hyaluronic acid, 0.3% lidocaine; HYC-24L, Allergan) with Belotero Balance (22.5 mg/ml hyaluronic acid; CPM-22.5, Merz Aesthetics) as treatment for 136 adults who had moderate-to-severe perioral lines. Read more.

    See more from American Academy of Dermatology